MYC and plasma cell myeloma: Selective targeting of ribosomal biogenesis by the small molecule inhibitor CX-5461 in MYC-dependent myeloma led to the inhibition of cell growth and reduction of MYC downstream target gene expression, thereby also overcoming drug resistance (141).